Overview

Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions

Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Abbott (TriCor) 160 mg fenofibrate tablets under fed conditions.
Phase:
N/A
Details
Lead Sponsor:
Ranbaxy Laboratories Limited
Treatments:
Fenofibrate